{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:38:43Z","timestamp":1790026723479,"version":"4.0.1"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nephrol."],"abstract":"<jats:p>Immunoglobulin A Nephropathy (IgAN) is a prevalent form of glomerulonephritis that leads to chronic kidney disease (CKD), typically marked by ongoing proteinuria, even when treated with standard therapies such as renin-angiotensin-aldosterone system (RAAS) blockers and occasionally immunosuppression. Proteinuria is a modifiable risk factor crucial for disease advancement. Sparsentan, a dual endothelin receptor and angiotensin receptor blocker (DEARA), has been introduced as a novel therapeutic option focusing on proteinuria. We present a case series featuring seven patients - five diagnosed with IgAN and two with IgA vasculitis (IgAV) - with severe proteinuria who were treated with Sparsentan, sometimes in combination with other medications such as targeted-release formulation (TRF) budesonide, sodium-glucose cotransporter-2 (SGLT2) inhibitors, or mycophenolate. Notable reductions in proteinuria and improvements in blood pressure regulation were observed in these cases. Sparsentan was well-tolerated overall, with no significant hyperkalemia or hepatotoxicity reported in this group. These cases emphasize the real-world experience, promising efficacy and safety of Sparsentan in reducing proteinuria in patients with IgA-mediated glomerular disorders, including its application in combination therapies and patients with concurrent or prior immunosuppression<\/jats:p>","DOI":"10.3389\/fneph.2025.1673799","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T14:17:58Z","timestamp":1763734678000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Maximizing the anti-proteinuric response: a multicenter real-world sparsentan case series in IgA disorders"],"prefix":"10.3389","volume":"5","author":[{"given":"Abhisekh Sinha","family":"Ray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Errabelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maulik","family":"Lathiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeharik","family":"Mareedu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1206793","article-title":"IGA NEPHROPATHY","volume":"368","author":"Wyatt","year":"2013","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"16001","DOI":"10.1038\/nrdp.2016.1","article-title":"IgA nephropathy","volume":"2","author":"Lai","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.02.003","article-title":"IgA vasculitis (Henoch-Sch\u00f6nlein purpura) in adults: Diagnostic and therapeutic aspects","volume":"14","author":"Audemard-Verger","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"Reich","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.243","article-title":"The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification","volume":"76","author":"Cattran","year":"2009","journal-title":"Kidney Int"},{"key":"B6","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with igA nephropathy: the TESTING randomized clinical trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.92a.24105","article-title":"IgA nephropathy: an update on pathogenesis and therapy","volume":"2","author":"Cox","year":"2021","journal-title":"Kidney360"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.143","article-title":"Endothelin antagonism in the management of kidney disease","volume":"86","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.09.015","article-title":"Management of IgA nephropathy: challenges, advances, and future directions","volume":"105","author":"Tesa\u0159","year":"2024","journal-title":"Kidney Int"},{"key":"B12","article-title":"WCN24\u20132352 Improved Proteinuria Reduction with the use of Sparsentan and Targeted Release Budesonide in advanced IgAN","volume":"9","author":"Mareedu","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","year":"2023","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"6621","DOI":"10.3390\/jcm13216621","article-title":"IgA vasculitis (Henoch\u2013sch\u00f6nlein purpura): an update on treatment","volume":"13","author":"Casta\u00f1eda","year":"2024","journal-title":"J Clin Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.09.017","article-title":"Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy","volume":"103","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1461879","article-title":"Therapy of IgA nephropathy: time for a paradigm change","volume":"11","author":"Perkovic","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.715253","article-title":"An Update on Targeted Treatment of IgA Nephropathy: An Autoimmune Perspective","volume":"12","author":"Huang","year":"2021","journal-title":"Front Pharmacol"},{"key":"B18","article-title":"WCN24\u20132219 TRF-Budesonide and Sparsentan as an initial therapy for primary IgA nephritis","volume":"9","author":"Mareedu","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.02.012","article-title":"Baseline characteristics of patients enrolled in the PROTECT study of sparsentan for the treatment of IgA nephropathy","volume":"7","author":"Komers","year":"2022","journal-title":"Kidney Int Rep"}],"container-title":["Frontiers in Nephrology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2025.1673799\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T14:18:00Z","timestamp":1763734680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2025.1673799\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":19,"alternative-id":["10.3389\/fneph.2025.1673799"],"URL":"https:\/\/doi.org\/10.3389\/fneph.2025.1673799","relation":{},"ISSN":["2813-0626"],"issn-type":[{"value":"2813-0626","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"article-number":"1673799"}}